Prevalence of Skin Diseases Accelerating the Dermatology Drugs Sector Growth

Dermatology drugs market is expected to reach $34.5 billion by 2023, according to P&S Intelligence.
 
 
Dermatology Drugs Market 5
Dermatology Drugs Market 5
 
Spread the Word
Listed Under

Tag:
* Dermatology Drugs Market

Industry:
* Reports

Location:
* Alhambra - California - US

Subject:
* Reports

ALHAMBRA, Calif. - July 7, 2019 - PRLog -- Increasing personal spending, strong pipeline of dermatological drugs, and growing awareness about skin diseases are the key factors boosting the demand for dermatology drugs globally.

On the basis of treatment, the dermatology drugs market has been categorized into topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others. Among these, biologics is expected to be the fastest growing category, advancing at CAGR of 9.1% during the forecast period.

Based on drug, the dermatology drugs market has been mainly classified into Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, and Eucrisa. Of these, Humira witnessed the highest demand in the market, majorly among patients suffering from psoriasis.

Access Detailed Report Summary:  https://www.psmarketresearch.com/market-analysis/dermatology-drug-market

Major therapy areas of dermatology drugs include psoriasis, atopic dermatitis, acne, rosacea, acne scars, and skin cancer. The dermatology drugs market saw the highest revenue generated from psoriasis drugs during the historical period. The category generated revenue of $14.2 billion in the market in 2017. The report also provides the analysis of various therapy areas, on the basis of prescription mode.

On the basis of distribution channel, the dermatology drugs market has been categorized into direct, wholesale/retail, and online channels. Of these, the fastest growth in the market during the forecast period is expected from direct distribution channels, with 8.5% CAGR. Besides, the major end users covered under the scope of the study are hospitals, clinics, cosmetic centers, and at-home users, where hospitals generated the highest revenue, amounting to $8.2 billion, in the market in 2017. This can be attributed to the availability of improved healthcare facilities and rising patient base in hospitals globally.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/dermatology-drug-market/report-sample (https://www.psmarketresearch.com/market-analysis/dermatol...)

During the forecast period, the dermatology drugs market is forecasted to witness the fastest growth in APAC, with 9.6% CAGR. This growth can be attributed to the increasing disposable income of people in the region, which is leading to the high adoption of skincare products, including dermatological drugs. Moreover, the increase in the number of skin cancer cases in the region is contributing to the high demand for these drugs.

Furthermore, several market players, as part of their business strategy, are exploring the untapped market in developing economies such as China and India, which, in turn, is supporting the growth of the APAC dermatology drugs market. For instance, in October 2017, Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical manufacturer, received approval from the Drug Controller General of India to launch Otezla, a new class of oral medication for psoriasis, after conducting clinical trials on psoriasis patients for 16 weeks. The approval and launch of new medications in developing countries are expected to boost the demand for dermatological drugs in APAC during the forecast period.

Some of the other key players in the dermatology drugs market (https://www.psmarketresearch.com/market-analysis/dermatol...) are Celgene Corporation, Bausch Health Companies Inc., Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Allergan plc, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Nestlé Skin Health S.A., GlaxoSmithKline plc, Mylan N.V., and LEO Pharma A/S.

Contact
Pramod Kumar
***@psmarketresearch.com
End
Email:***@psmarketresearch.com Email Verified
Tags:Dermatology Drugs Market
Industry:Reports
Location:Alhambra - California - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
P&S Intelligence News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share